Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Non-Current Assets came in at $938.6 million in Q2 2026, up 1.76% YoY from $922.3 million in Q2 2025, and up 3.12% on a QoQ basis from $910.2 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Non-Current Assets (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Non-Current Assets data on file, last reported at $938.6 million in Q2 2026.
- Quarterly Non-Current Assets rose 1.76% year-over-year to $938.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.7 billion (changed 0.03% YoY) and the FY2025 annual result came in at $915.7 million, down 3.07% from the prior year.
- Non-Current Assets improved to $938.6 million in Q2 2026, from $910.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $945.6 million in Q1 2025 to a low of $835.8 million in Q1 2024.
- A 5-year average of $879.4 million and a median of $856.4 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets retreated 4.73% — and 2025, when it gained 13.13%.
- Tracing ALNY's Non-Current Assets over 5 years: stood at $854.1 million in 2022, then retreated by 0.81% to $847.2 million in 2023, then climbed by 11.51% to $944.7 million in 2024, then retreated by 3.07% to $915.7 million in 2025, then rose by 2.5% to $938.6 million in 2026.
- The last three Non-Current Assets figures came in at $938.6 million (Q2 2026), $910.2 million (Q1 2026), and $915.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 938.60 Mn |
| Mar 31, 2026 | 910.24 Mn |
| Dec 31, 2025 | 915.67 Mn |
| Sep 30, 2025 | 898.85 Mn |
| Jun 30, 2025 | 922.32 Mn |
| Mar 31, 2025 | 945.55 Mn |
| Dec 31, 2024 | 944.70 Mn |
| Sep 30, 2024 | 849.62 Mn |
| Jun 30, 2024 | 836.78 Mn |
| Mar 31, 2024 | 835.78 Mn |
| Dec 31, 2023 | 847.18 Mn |
| Sep 30, 2023 | 853.62 Mn |
| Jun 30, 2023 | 878.35 Mn |
| Mar 31, 2023 | 850.92 Mn |
| Dec 31, 2022 | 854.11 Mn |
| Sep 30, 2022 | 844.41 Mn |
| Jun 30, 2022 | 858.78 Mn |
| Mar 31, 2022 | 843.87 Mn |
| Dec 31, 2021 | 834.73 Mn |
| Sep 30, 2021 | 796.95 Mn |